Skip to main content
SpringerLink
Log in

Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools

  • Chapter
Breast Cancer

  • 1864 Accesses

Abstract

Breast cancer heterogeneity represents a major hurdle to improve patient survival. Notwithstanding its potential curability due to the availability of treatment modalities that are effective in the presence of favourable clinical or patho-biologic features, there is still a great deal of controversy in its clinical management. In the last decades, tumour biomarkers that are indicative of or related to cell traits characterising malignancy, such as self-sufficiency in proliferative growth signals, insensitivity to growth inhibitory signals, evasion of apoptosis, limitless replicative potential, activation of pathways leading to neo-angiogenesis, invasion and metastasis, have provided information that have proved to be associated with disease progression. However, when singly analysed, their prognostic relevance was modest, and the only clinically useful biomarkers that remained are cell proliferation and plasminogen activationrelated factors for prognosis, steroid hormone receptors and HER2/neu for prediction of response to hormonal or to the novel targeted anti-HER2/neu therapy, respectively. It therefore remains necessary to reduce the intrinsic complexity of breast cancer in order to improve its clinical outcome. One way to achieve this objective derives directly from the concept that cancer is a genetic disease at the somatic level and from the recent availability of high-throughput post-genomic analytical tools such as gene and protein expression techniques for global gene expression analysis. The knowledge derived from gene expression-profiling studies is impressive and challenges currently used breast cancer classification and existing theories about metastatic progression and breast cancer biology. Several studies employing this technology have been consistent in reproducing a molecular classification for breast cancer in which: (1) oestrogen receptor status and tumour grade are the most important discriminators of gene expression subgroups; (2) tumours can be grouped into at least four subsets according to steroid receptor and HER2/neu status; (3) each subset of tumours has a distinct clinical outcome and may therefore respond differentially to various treatments. Additionally, prognostic gene expression signatures have been proposed that outperform traditional clinical risk classification systems, suggesting the possibility to reduce over-treatment in early breast cancer, notwithstanding that the identification of high-risk patients still needs to be improved. A number of recent studies have been directed to answer different clinical and biological questions. However, despite initial enthusiasm doubts have been raised recently regarding the reliability of gene expression profiling for clinical applications, and the outcome of these novel studies still needs to be validated with the cooperation of different specialists and the integration between all the different skills involved in translational research in oncology.

On behalf of the PathoBiology Group of the European Organization for Research and Treatment of Cancer (PBG-EORTC)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Molecular Med 7:542–547

    Article  CAS  Google Scholar 

  • Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581–8589

    Article  PubMed  CAS  Google Scholar 

  • Amadori D, Nanni O, Marangolo M et al (2000) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with node-negative rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 18:3125–3134

    PubMed  CAS  Google Scholar 

  • Andre F, Khalil A, Slimane K, Massard C, Mathieu MC, Vignot S, Assi H, Delaloge S, Spielmann M (2005) Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol 23:2996–3000

    Article  PubMed  CAS  Google Scholar 

  • Arciero C, Somiari SB, Shriver CD, Brzeski H, Jordan R, Hu H, Ellsworth DL, Somiari RI (2004) Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers 18:241–272

    Google Scholar 

  • Arora R, Joshi K, Nijhawan R et al (2002) Angiogenesis as an independent prognostic indicator in node-negative breast cancer. Anal Quant Cytol Histol 24:228–233

    PubMed  Google Scholar 

  • Baak JP, van Diest PJ, Benraadt T et al (1993) The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) in the Netherlands; value of morphometrically assessed proliferation and differentiation. J Cell Biochem [Suppl] 17G:220–225

    Article  CAS  Google Scholar 

  • Baak JPA, van Diest PJ, Voorhorst FJ, van der Wall E, Beek LVAM, Vermorken JB, Janssen EAM (2005) Prospective multicentri calidation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23:5993–6001

    Article  PubMed  Google Scholar 

  • Baldetorp B, Bendahl PO, Ferno M et al (1995) Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories’ results for 67 sample homogenates. Cytometry 22:115–127

    Article  PubMed  CAS  Google Scholar 

  • Bast RC, Ravdin P, Hayes DF et al (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878

    PubMed  Google Scholar 

  • Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R (2000) p27Kip1 expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer (Pred Oncol) 89:236–241

    Article  PubMed  CAS  Google Scholar 

  • Barnes A, Pinder SE, Bell JA, Paish EC, Wencyk PM, Robertson JFR, Elston CW, llis IO (2003) Expressoin of p27kip1 in breast cancer and its prognostic significance. J Pathol 201:451–459

    Article  PubMed  CAS  Google Scholar 

  • Bibikova M, Yeakley JM, Chudin E, Chen J, Wickham E, Wang-Rodriguez J, Fan JB (2004) Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis. Clin Chem 50:2384–2386

    Article  PubMed  CAS  Google Scholar 

  • Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y, Fan JB (2004) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 2004; 165:1799–1807

    PubMed  CAS  Google Scholar 

  • Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357

    Article  PubMed  CAS  Google Scholar 

  • Borg A, Fernö M, Peterson C (2003) Predicting the future of breast cancer. Nature medicine 9:16–18

    Article  PubMed  CAS  Google Scholar 

  • Bos R, van der Groep P, Greijer AE et al (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis inpatients with lymph node negative breast carcinoma. Cancer 97:1573–1581

    Article  PubMed  Google Scholar 

  • Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B (1998) S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 51:239–253

    Article  PubMed  CAS  Google Scholar 

  • Bukholm IR, Bukholm G, Nesland JM (2001) Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 3:283–287

    Article  Google Scholar 

  • Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 8:R31

    Article  PubMed  CAS  Google Scholar 

  • Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192

    PubMed  CAS  Google Scholar 

  • Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227–230

    Article  PubMed  CAS  Google Scholar 

  • Chang J, Clark GM, Allred D et al (2003) Survival of patients with metastatic breast cancer: importance of prognostic markers of the primary tumor. Cancer 97:545–553

    Article  PubMed  Google Scholar 

  • Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2:E7

    Article  PubMed  CAS  Google Scholar 

  • Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet J-S, Narod SA, Slingerland J, Foulkes WD (2000) Germline BRCA1/2 mutaions and p27Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045–4052

    PubMed  CAS  Google Scholar 

  • Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3:e47

    Article  PubMed  CAS  Google Scholar 

  • Chu JS, Huang CS, Chang KJ (1999) p27 expression as a prognostic factor of breast cancer in Taiwan. Cancer Letter 141:123–130

    Article  CAS  Google Scholar 

  • Collan YU, Kuopio T, Baak JP et al (1996) Standardized mitotic counts in breast cancer. Evaluation of the method. Pathol Res Pract 192:931–941

    PubMed  CAS  Google Scholar 

  • Coradini D, Boracchi P, Daidone MG, Pellizzaro C, Miodini P, Ammatuna M, Tomasic G, Biganzoli E (2001) Prognostic contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer 85: 795–797

    Article  PubMed  CAS  Google Scholar 

  • Coradini D, Biganzoli E, Pellizzaro C et al (2003) Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. Br J Cancer 89:268–270

    Article  PubMed  CAS  Google Scholar 

  • Daidone MG, Silvestrini R (2001) Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 30: 27–35

    PubMed  Google Scholar 

  • Daidone MG, Della Porta C, Pilotti S, Zaffaroni N (2002) Coexpression of survivin and hTERT in soft tissue sarcoma. Lancet 360:877

    Article  PubMed  Google Scholar 

  • Dazzi C, Cariello A, Maioli P et al (2003) A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. Cancer Invest 21:208–216

    Article  PubMed  CAS  Google Scholar 

  • Desmedt C, Sotiriou C (2006) Proliferation. The most prominent predictor of clinical outcome in breast cancer. Cell Cycle 5:2198–2202

    PubMed  CAS  Google Scholar 

  • Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A’Hern R (2006) Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 12:1024s–1030s

    Article  PubMed  CAS  Google Scholar 

  • Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM (1998) Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopahological parameters. Int J Cancer (Pred Oncol) 79:71–75

    Article  PubMed  CAS  Google Scholar 

  • EORTC Breast Cancer Cooperative Group (1980) Revision of the standard for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16:1513–1515

    Google Scholar 

  • Euler U, Meisner C, Friedel C, Schmidt M, Untch M, Lisboa B, Jaenicke F, Schmitt M, Thomssen C, Harbeck N (2006) Comparison of outcome prediction in node-negative breast cancer based on biomarkers uPA/PAI-1 or Adjuvant Online™ using the 10-year follow-up of the randomized multicenter Chemo N0 trial. ASCO Proceedings

    Google Scholar 

  • Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van’t Veer LJ, Perou CM (2006) Concordance among geneexpression-based predictors for breast cancer. N Engl J Med 355:560–569

    Article  PubMed  CAS  Google Scholar 

  • Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978

    PubMed  CAS  Google Scholar 

  • Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101–6105

    PubMed  CAS  Google Scholar 

  • Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F, Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648–1658

    PubMed  CAS  Google Scholar 

  • Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM (1995) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 predict poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst87: 751–756

    Article  CAS  Google Scholar 

  • Foulkes WD, Brunet J-S, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA (2004) The prognostic implication of the basal-like (cyclin Ehigh/ p27low/ p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835

    Article  PubMed  CAS  Google Scholar 

  • Geurts-Moespot J, Leake R, Benraad TJ, Sweep CG (2000) Twenty years of experience with the steroid receptor external quality assessment program-the paradigm for tumour biomarker EQA studies. On behalf of the EORTC Receptor and Biomarker Study Group. Int J Oncol 17:13–22

    PubMed  CAS  Google Scholar 

  • Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiules in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265–7277

    Article  PubMed  CAS  Google Scholar 

  • Gillett CE, Smith P, Peters G, Lu X, Barnes DM (1999) Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 187:200–206

    Article  PubMed  CAS  Google Scholar 

  • Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521

    Article  PubMed  CAS  Google Scholar 

  • Gohring UJ, Bersch A, Becker M, Neuhaus W, Schondorf T (2001) p21(waf) correlates with DANN replication but not with prognosis in invasive breast cancer. J Clin Pathol 54:866–870

    PubMed  CAS  Google Scholar 

  • Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2005) Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583

    Article  PubMed  CAS  Google Scholar 

  • Han S, Park K, Bae B-N, Kim KH, Kim H-J, Kim Y-D, Kim H-Y (2003) Prognostic implications of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83: 241–247

    Article  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  • Hansen S, Overgaard J, Rose C et al (2003) Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer 88:102–108

    Article  PubMed  CAS  Google Scholar 

  • Harbeck N, Kates RE, Look MP et al (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3,424). Cancer Res 62:4617–4622

    PubMed  CAS  Google Scholar 

  • Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M (2004) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 91:450–456

    PubMed  CAS  Google Scholar 

  • Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456–1466

    Article  PubMed  CAS  Google Scholar 

  • Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M (1998) CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102. Proceedings of the 34th Annual Meeting of the American Association of Cancer Research. Abstract # 2

    Google Scholar 

  • Ioachim E, Charchanti A, Briasoulis E et al (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38:2362–2370

    Article  PubMed  CAS  Google Scholar 

  • Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54:2527–2530

    PubMed  CAS  Google Scholar 

  • Janicke F, Prechtl A, Thomssen C et al (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type. J Natl Cancer Inst 93:913–920

    Article  PubMed  CAS  Google Scholar 

  • Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson E et al (2001) Low proliferative rate of invasive nodenegative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients. Clin Breast Cancer 1:310–314

    Article  PubMed  CAS  Google Scholar 

  • Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson E et al (2002) Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer. Clin Breast Cancer 3:147–152

    PubMed  Google Scholar 

  • Kennedy SM, O’Driscoll L, Purcell R et al (2003) Prognostic importance of survivin in breast cancer. Br J Cancer 88:1077–1083

    Article  PubMed  CAS  Google Scholar 

  • Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575

    Article  PubMed  CAS  Google Scholar 

  • Kühling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, Rudolph P (2003) Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 199:424–431

    Article  PubMed  CAS  Google Scholar 

  • Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C (2001) p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 67:15–22

    Article  PubMed  CAS  Google Scholar 

  • Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J (2004) Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 25:375–380

    Article  PubMed  CAS  Google Scholar 

  • Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226

    Article  PubMed  CAS  Google Scholar 

  • Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fern Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelénat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Küng W, Beex LVAM, Klijn JGM, O’Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8,377 breast cancer patients. J Natl Cancer Inst 94

    Google Scholar 

  • Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Foekens JA, Beex LV, Sweep CG (2004) Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 64:659–664

    Article  PubMed  CAS  Google Scholar 

  • Massague J (2007) Sorting out breast-cancer gene signatures. N Engl J Med 356:294–297

    Article  PubMed  CAS  Google Scholar 

  • Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt, Huldij J, van Diest P (2002) Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 86:402–404

    Article  PubMed  CAS  Google Scholar 

  • Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524

    Article  PubMed  CAS  Google Scholar 

  • Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115:44–55

    Article  PubMed  CAS  Google Scholar 

  • National Institutes of Health Consensus Development Conference Statement (2001) Adjuvant Therapy for Breast Cancer, November 1–3, 2000. J Natl Cancer Inst 93:979–989

    Article  Google Scholar 

  • Nohara T, Ryo T, Iwamoto S, Gon G, Tanigawa N (2001) Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 60:94–100

    Article  PubMed  CAS  Google Scholar 

  • O’Hanlon DM, Fitzsimons H, Lynch J et al (2002) Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38:2252–2257

    Article  PubMed  CAS  Google Scholar 

  • Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826

    Article  PubMed  CAS  Google Scholar 

  • Paik S, Tang G, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 23:3726–3734

    Article  CAS  Google Scholar 

  • Paradiso A, Schittulli F, Cellamare G, Mangia A, Marzullo F, Lorusso V, De Lena M (2001) Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 19:3929–3937

    PubMed  CAS  Google Scholar 

  • Paradiso A, Volpe S, Iacobacci A, Marubini E, Verderio P, Costa A et al (2002) Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumour Biomarkers (INQAT). Int J Biol Markers 2002; 17:201–214

    PubMed  CAS  Google Scholar 

  • Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  PubMed  CAS  Google Scholar 

  • Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222–225

    Article  PubMed  CAS  Google Scholar 

  • Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF (2006) p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst. 98:1723–1731

    Article  PubMed  CAS  Google Scholar 

  • Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685

    Article  PubMed  CAS  Google Scholar 

  • Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, Olsson H, Parwaresch R (2003) Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105:674–680

    Article  PubMed  CAS  Google Scholar 

  • Schiller AB, Clark WS, Cotsonis G, et al. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis. Cytometry 2002; 50:203–209

    Article  PubMed  CAS  Google Scholar 

  • Silvestrini R, Luisi A, Zambetti M, Cipriani S, Valagussa P, Bonadonna G, et al. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. Int J Cancer 2000; 87:405–411

    Article  PubMed  CAS  Google Scholar 

  • Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261–2267

    Article  PubMed  CAS  Google Scholar 

  • Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874

    Article  PubMed  CAS  Google Scholar 

  • Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398

    Article  PubMed  CAS  Google Scholar 

  • Span PN, Tjan-Heijnen VCG, Manders P, Beex LVAM, Sweep CGJ (2003) Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22:4898–4904

    Article  PubMed  CAS  Google Scholar 

  • Sweep CGJ, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJTM, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ (1998) External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78:1434–1441

    PubMed  CAS  Google Scholar 

  • Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57:1259–1263

    PubMed  CAS  Google Scholar 

  • Thomssen C, Janicke F, Harbeck N (2003) Clinical relevance of prognostic factors in axillary node-negative breast cancer. Onkologie 26:438–445

    Article  PubMed  CAS  Google Scholar 

  • Thor AD, Liu S, Moore II DH, Shi Q, Edgerton SM (2000) P21WAF1/CIP1 expression in breast cancer: associations with p53 and outcome. Breast Cancer Res Treat 61:33–43

    Article  PubMed  CAS  Google Scholar 

  • Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Expression of maspin predicts poor prognosis in breast cancer patients. Int J Cancer 100:452–455

    Article  PubMed  CAS  Google Scholar 

  • Urriticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220

    Article  CAS  Google Scholar 

  • Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, Scarpi E, Riccobon A, Balzi M, Amadori D (2000) Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 63:181–192

    Article  PubMed  CAS  Google Scholar 

  • van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536

    Article  Google Scholar 

  • van de Vijer MJ, He YD, van’t Veer LJ et al (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009

    Article  Google Scholar 

  • Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679

    PubMed  CAS  Google Scholar 

  • Watson PH, Chia SK, Wykoff CC et al (2003) Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer 88:1065–1070

    Article  PubMed  CAS  Google Scholar 

  • Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nature Reviews Cancer 6:99–106

    Article  PubMed  CAS  Google Scholar 

  • Wu Z, Shen Z-Z, Lu J-S, Jiang M, Han Q-X, Fontana JA, Barsky SH, Shao Z-M (1999) Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 79:1572–1578

    Article  PubMed  CAS  Google Scholar 

  • Yang Q, Sakurai T, Yoshimura G et al (2003) Prognostic value of bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 10:121–125

    PubMed  CAS  Google Scholar 

  • Zemzoum I, Kates RE, Ross JS et al (2003) Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in nodenegative breast cancer. J Clin Oncol 21:1022–1028

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Unit 10 Department of Experimental Oncology Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

    Maria Grazia Daidone & Vera Cappelletti

  2. Department of Experimental Oncology, Istituto Oncologico, Bari, Italy

    Angelo Paradiso

  3. Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, Venice, Italy

    Massimo Gion

  4. Clinical Research Unit Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany

    Nadia Harbeck

  5. Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands

    Fred Sweep & Manfred Schmitt

Authors
  1. Maria Grazia Daidone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera Cappelletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelo Paradiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimo Gion
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nadia Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fred Sweep
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manfred Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Nuclear Medicine Department of Diagnostic Imaging and Radiotherapy Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milano, Italy

    Emilio Bombardieri MD

  2. Division of Medical Oncology Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milano, Italy

    Luca Gianni MD

  3. Perspective Clinical Trials Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milano, Italy

    Gianni Bonadonna MD (Chair) (Chair)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Daidone, M.G. et al. (2008). Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. In: Bombardieri, E., Gianni, L., Bonadonna, G. (eds) Breast Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-36781-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-36781-9_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-36780-2

  • Online ISBN: 978-3-540-36781-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation